PMID- 30205105 OWN - NLM STAT- MEDLINE DCOM- 20190522 LR - 20200225 IS - 1527-9995 (Electronic) IS - 0090-4295 (Print) IS - 0090-4295 (Linking) VI - 122 DP - 2018 Dec TI - Antimuscarinic Use in Men Treated With Bladder Outlet Obstruction Medication Therapy. PG - 76-82 LID - S0090-4295(18)30946-4 [pii] LID - 10.1016/j.urology.2018.08.039 [doi] AB - OBJECTIVE: To assess changes over time in the use of antimuscarinics (AM) among visits in adult men treated with bladder outlet obstruction (BOO) medication therapy (ie, alpha blocker and 5-alpha reductase inhibitors). METHODS: We used the National Ambulatory Medicare Care Survey database (2006-2014) to identify men aged 40 or older, who initiated or continued on BOO medication therapy. Among these visits, we assessed the percentage of AM and evaluated trends of AM use across between 2006 and 2014 using multivariable logistic regression. RESULTS: Overall, there were 7561 patient visits in men aged 40 or older, who were treated with BOO medication therapy between 2006 and 2014 which equates to approximately 158 million visits in the United States after incorporating National Ambulatory Medicare Care Survey weights. Overall, AM was used in 3.7% of visits, among those who were treated with BOO medication therapy; use of AM increased with age. In the multivariable analysis, there was no increasing trend in the use of AM in 2006 relative to subsequent years through 2014 (P = .8104). CONCLUSION: Despite a previous study that showed an increasing trend in antimuscarinic use among patients coded for lower urinary tract symptoms or benign prostatic hyperplasia between 1993 and 2010, several recent randomized-controlled trials, and a recommendation in a clinical practice guideline in 2010, we found no increasing trend in antimuscarinic use among visits in men who were treated with BOO medication therapy in 2006 compared to subsequent years. This suggests the potential undertreatment of antimuscarinics and an area for improved prescribing. CI - Copyright (c) 2018 Elsevier Inc. All rights reserved. FAU - Vouri, Scott Martin AU - Vouri SM AD - Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL; University of Florida Health Physicians, Gainesville, FL. Electronic address: svouri@cop.ufl.edu. FAU - Strope, Seth A AU - Strope SA AD - Department of Urologic Surgery, Baptist MD Anderson Cancer Center, Jacksonville, FL. FAU - Olsen, Margaret A AU - Olsen MA AD - Department of Internal Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO. FAU - Xian, Hong AU - Xian H AD - College of Public Health and Social Justice, Saint Louis University, St. Louis, MO. FAU - Schootman, Mario AU - Schootman M AD - SSM Health, Department of Clinical Analytics and Insights, St. Louis, MO. LA - eng GR - KL2 TR000450/TR/NCATS NIH HHS/United States GR - KL2 TR002346/TR/NCATS NIH HHS/United States GR - UL1 TR000448/TR/NCATS NIH HHS/United States GR - UL1 TR002345/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20180908 PL - United States TA - Urology JT - Urology JID - 0366151 RN - 0 (5-alpha Reductase Inhibitors) RN - 0 (Adrenergic alpha-Antagonists) RN - 0 (Muscarinic Antagonists) SB - IM CIN - J Urol. 2020 Mar;203(3):439-440. PMID: 31841073 MH - 5-alpha Reductase Inhibitors/therapeutic use MH - Adrenergic alpha-Antagonists/therapeutic use MH - Adult MH - Aged MH - Aged, 80 and over MH - Cross-Sectional Studies MH - Databases, Factual/statistics & numerical data MH - Drug Prescriptions/statistics & numerical data MH - Drug Therapy, Combination/methods/statistics & numerical data MH - Drug Utilization/*statistics & numerical data/trends MH - Humans MH - Male MH - Medicare/statistics & numerical data MH - Middle Aged MH - Muscarinic Antagonists/*therapeutic use MH - Prostatic Hyperplasia/complications/*drug therapy MH - United States MH - Urinary Bladder Neck Obstruction/*drug therapy/etiology PMC - PMC6393110 MID - NIHMS1013341 COIS- Conflict of Interest: The authors disclose no financial conflicts of interests EDAT- 2018/09/12 06:00 MHDA- 2019/05/23 06:00 PMCR- 2019/12/01 CRDT- 2018/09/12 06:00 PHST- 2018/07/05 00:00 [received] PHST- 2018/08/01 00:00 [revised] PHST- 2018/08/28 00:00 [accepted] PHST- 2018/09/12 06:00 [pubmed] PHST- 2019/05/23 06:00 [medline] PHST- 2018/09/12 06:00 [entrez] PHST- 2019/12/01 00:00 [pmc-release] AID - S0090-4295(18)30946-4 [pii] AID - 10.1016/j.urology.2018.08.039 [doi] PST - ppublish SO - Urology. 2018 Dec;122:76-82. doi: 10.1016/j.urology.2018.08.039. Epub 2018 Sep 8.